We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech ...

REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.

Despite a much-needed update, Spider-Verse movie fans are still concerned over a potential delay to the trilogy capper's ...

Fintel reports that on April 13, 2026, Leerink Partners downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Market Perform. Analyst Price Forecast Suggests 641.98% Upside ...

Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...

Replimune Group criticized a Food and Drug Administration decision to deny its application for a melanoma treatment in a review process that the clinical-stage biotechnology company said was marked by ...

The Food and Drug Administration rejected Replimune Group's application for an advanced melanoma drug for a second time.

Shares of Replimune Group continued their free fall and touched an all-time low after the company's application for a melanoma treatment was rejected by the Food and Drug Administration for a second ...

Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating. Read why IOVA stock is a Buy.

What is Grok? Explore Elon Musk’s AI chatbot with real-time X data, bold personality, advanced features, pricing, risks, and ...

Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions ...

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...